Cynomolgus Anti-Rubella virus Glycoprotein E2 Antibody IgG Titer Serologic Assay Kit (ELISA)
Cat. No. RAS-T232
Glycoprotein E2 Product List
Species
- RUBV（2）
| Cat. No. | Product Name | Size&Price | Add to Cart |
|---|---|---|---|
Cynomolgus Anti-Rubella virus Glycoprotein E2 Antibody IgG Titer Serologic Assay Kit (ELISA) | $670.00 96tests |   | |
Cynomolgus Anti-Mumps virus Fusion glycoprotein F0 Antibody IgG Titer Serologic Assay Kit (ELISA) | $670.00 96tests | |
Cynomolgus Anti-Mumps virus Fusion glycoprotein F0 Antibody IgG Titer Serologic Assay Kit (ELISA)
Cat. No. RAS-T233
You Have Viewed 1-2 Of 2 Results
Asset Licensing Opportunity
Resources
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Uliledlimab | TJ-4309; TJ-004309; TJD-5 | Phase 3 Clinical | I-Mab Biopharma Co Ltd | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis | Details |
| Quemliclustat | AB-680 | Phase 3 Clinical | Arcus Biosciences Inc | Biliary Tract Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Cholangiocarcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| Oleclumab | MEDI-9447 | Phase 3 Clinical | Medimmune Llc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Hemangiosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Liposarcoma; Prostatic Neoplasms; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Dalutrafusp alfa | GS-1423; AGEN-1423 | Phase 2 Clinical | Agenus Inc | Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| Interferon beta-1a (Faron Pharmaceuticals) | MR-11A8; FP-1201; FP-1201-lyo | Phase 2 Clinical | Faron Pharmaceuticals Ltd | Multiple Organ Failure; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Acute Lung Injury | Details |
| BMS-986179 | BMS-986179 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details |
| Mupadolimab | CPX-006; COR-004 (Corvus Pharmaceuticals); CPI-006 | Phase 2 Clinical | Corvus Pharmaceuticals Inc | Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| Dresbuxelimab | AK-119 | Phase 2 Clinical | Akeso Pharmaceuticals Inc | Solid tumours; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| S-095024 | S-095024; S095024 | Phase 2 Clinical | Institut De Recherches Internationales Servier, Servier Bio-Innovation LLC | Carcinoma, Non-Small-Cell Lung | Details |
| HB-0045 | HB-0045; HB0045 | Phase 2 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
| JAB-BX102 | JAB-BX102 | Phase 2 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details |
| LY-3475070 | LY-3475070 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details |
| Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details | |
| Uprevstobart | INCA-00186 | Phase 1 Clinical | Incyte Corp Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Gastrointestinal Neoplasms | Details |
| HB-0052 | HB-0052; HB0052 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
| BPI-472372 | BPI-472372 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| BB-1709 | BB-1709 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours | Details |
| PM-1015 | PM1015; PM-1015 | Phase 1 Clinical | Biotheus Inc | Solid tumours | Details |
| AK-131 | AK-131 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| PT-199 | PT-199 | Phase 1 Clinical | Phanes Therapeutics Inc | Solid tumours; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| IBI-325 | IBI-325 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| BR-101 | BR101; BR-101 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
| CB-708 | CB-708; CB708; ATG-037 | Phase 1 Clinical | Calithera Biosciences Inc | Solid tumours; Neoplasms | Details |
| HLX-23 | HLX-23 | Phase 1 Clinical | Solid tumours; Lymphoma | Details | |
| ORIC533 | ORIC-533 | Phase 1 Clinical | Oric Pharmaceuticals Inc | Multiple Myeloma; Neoplasm Metastasis | Details |
| IPH-5301 | IPH-5301 | Phase 1 Clinical | Innate Pharma | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Neoplasm Metastasis | Details |
| HBM-1007 | HBM1007; R 1007; HBM 1007; HBM-1007 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Neoplasms | Details |
| ABSK-051 | ABSK051 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Neoplasms | Details |
Customer Reviews